

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

Claims 1-12 (Cancelled).

13(Currently amended). A method for preparing a composition for treating a viral infection, ~~said method~~ comprising deriving ~~autologous~~ lymphocytes from a virally infected patient and culturing said ~~autologous~~ lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said ~~autologous~~ lymphocytes which are effective against viral infections, with the proviso that said virally-infected patient is not a cytomegalovirus-infected patient.

14(Currently amended). A method for treating a viral infection, said method comprising deriving ~~autologous~~ lymphocytes from a virally infected patient, culturing said ~~autologous~~ lymphocytes in a culture medium comprising anti-CD3 antibodies in a solid phase and interleukin-2 to proliferate and activate *in vitro* said ~~autologous~~ lymphocytes, and administering said activated ~~autologous~~ lymphocytes which are effective against viral infections to said patient from which said ~~autologous~~ lymphocytes were derived.

Claims 15-18 (Cancelled).

19(Currently amended). The method according to claim 13, wherein said *in vitro* proliferated and activated ~~autologous~~ lymphocytes are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

20(Previously presented). The method according to claim 19, wherein a protein is added to said cell-suspended solution.

21(Previously presented). The method according to claim 20, wherein said protein is human albumin.

22(Previously presented). The method according to claim 13, wherein said culture medium further comprises cytokines.

23(Currently amended). The method according to claim 14, wherein said *in vitro* activated ~~autologous~~ lymphocytes are suspended in a buffer solution of physiological saline or phosphate buffer solution to make a cell-suspended solution, and administered to said patient.

24(Previously presented). The method according to claim 23, wherein a protein is added to said cell-suspended solution.

25(Previously presented). The method according to claim 24, wherein said protein is human albumin.

26(Currently amended). The method according to claim 23, wherein said activated ~~autologous~~ lymphocytes having a cell concentration in the range of 1×10^4 parts/lit. to 1×10^8 parts/lit. are administered to same patient at a time.

27(Currently amended). The method according to claim ~~23~~ 14, wherein said culture medium further comprises cytokines.

Claims 28-30 (Cancelled).

31(Previously presented). The method according to claim 13, wherein said viral infection is an Epstein-Barr viral infection.

32(Previously presented). The method according to claim 14, wherein said patient is virally infected, immunodeficient or immunosuppressed due to an Epstein-Barr viral infection.

Claim 33 (Cancelled).

34(Previously presented). The method according to claim 13, wherein said viral infection is a herpes simplex viral infection.

Claim 35 (Cancelled).

36(Currently amended). The method according to claim 13, wherein the activated ~~autologous~~ lymphocytes are T-lymphocytes.

37(Currently amended). The method according to claim 14, wherein the activated ~~autologous~~ lymphocytes are T-lymphocytes.

38(Previously presented). The method according to claim 13, wherein the viral infection is a herpes group viral infection.

Claims 39 (Cancelled).